{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T22:25:48Z","timestamp":1783981548730,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1186\/s12886-018-0861-8","type":"journal-article","created":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T09:06:00Z","timestamp":1536915960000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["New features in MEK retinopathy"],"prefix":"10.1186","volume":"18","author":[{"given":"Pallavi","family":"Tyagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,14]]},"reference":[{"key":"861_CR1","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","volume":"29","author":"GV Long","year":"2011","unstructured":"Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29:1239\u201346.","journal-title":"J Clin Oncol"},{"issue":"18","key":"861_CR2","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","volume":"367","author":"Keith T. Flaherty","year":"2012","unstructured":"Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J.Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. N Engl J Med. 2012;367(18):1694\u2013703.","journal-title":"New England Journal of Medicine"},{"key":"861_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2147\/DHPS.S39568","volume":"6","author":"JJ Luke","year":"2014","unstructured":"Luke JJ, Ott PA. New developments in the treatment of metastatic melanoma\u2014 role of dabrafenib-trametinib combination therapy. Drug Healthc Patient Saf. 2014;6:77\u201388.","journal-title":"Drug Healthc Patient Saf"},{"key":"861_CR4","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1158\/1078-0432.CCR-13-2054","volume":"20","author":"AM Menzies","year":"2014","unstructured":"Menzies AM, Long GV. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Clin Cancer Res. 2014;20:2035\u201343.","journal-title":"Clin Cancer Res"},{"key":"861_CR5","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1093\/annonc\/mdw100","volume":"27","author":"N Stjepanovic","year":"2016","unstructured":"Stjepanovic N, Velazquez-Martin JP, Bedard PL. Ocular toxicities of MEK inhibitors and other targeted therapies. Ann Oncol. 2016;27:998\u20131005.","journal-title":"Ann Oncol"},{"key":"861_CR6","first-page":"21153","volume":"52","author":"R Velez-Montoya","year":"2011","unstructured":"Velez-Montoya R, Olson J, Petrash M, et al. Acute onset central serous retinopathy in association with Mek inhibitor use for metastatic cancer. Invest Ophthalmol Vis Sci. 2011;52:21153.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"861_CR7","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ctrv.2013.01.003","volume":"39","author":"R van der Noll","year":"2013","unstructured":"van der Noll R, Leijen S, Neuteboom GH, et al. Effect of inhibition of the FGFR- MAPK signaling pathway on the development of ocular toxicities. Cancer Treat Rev. 2013;39:664\u201372.","journal-title":"Cancer Treat Rev"},{"key":"861_CR8","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdu169","volume":"25","author":"U Urner-Bloch","year":"2014","unstructured":"Urner-Bloch U, Urner M, Stieger P, et al. Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Ann Oncol. 2014;25:1437\u201341.","journal-title":"Ann Oncol"},{"key":"861_CR9","first-page":"673796","volume":"2013","author":"SD Schoenberger","year":"2013","unstructured":"Schoenberger SD, Kim SJ. Bilateral multifocal central serous-like chorioretinopathy due to MEK inhibition for metastatic cutaneous melanoma. Case Rep Ophthalmol Med. 2013;2013:673796.","journal-title":"Case Rep Ophthalmol Med"},{"issue":"8","key":"861_CR10","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/eye.2015.82","volume":"29","author":"KE Duncan","year":"2015","unstructured":"Duncan KE, Chang LY, Patronas M. MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity. Eye. 2015;29(8):1003\u201312.","journal-title":"Eye"},{"issue":"9","key":"861_CR11","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/j.ophtha.2015.05.027","volume":"122","author":"EH van Dijk","year":"2015","unstructured":"van Dijk EH, van Herpen CM, Marinkovic M, Haanen JB, Amundson D, Luyten GP, Jager MJ, Kapiteijn EH, Keunen JE, Adamus G, Boon CJ. Serous retinopathy. Associated with mitogen-activated protein kinase kinase inhibition (Binimetinib) for metastatic cutaneous and uveal melanoma. Ophthalmology. 2015 Sep;122(9):1907\u201316.","journal-title":"Ophthalmology"},{"issue":"8","key":"861_CR12","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1001\/jamaophthalmol.2016.0090","volume":"134","author":"ML Weber","year":"2016","unstructured":"Weber ML, Liang MC, Flaherty KT, Heier JS. Subretinal fluid associated with MEK inhibitor use in the treatment of systemic Cancer. JAMA Ophthalmol. 2016 Aug 1;134(8):855\u201362.","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"861_CR13","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.ajo.2015.07.035","volume":"160","author":"A Niro","year":"2015","unstructured":"Niro A, Strippoli S, Alessio G, Sborgia L, Recchimurzo N, Guida M. Ocular. Toxicity in metastatic melanoma patients treated with mitogen-activated protein kinase kinase inhibitors: a case series. Am J Ophthalmol. 2015 Nov;160(5):959\u201367.","journal-title":"Am J Ophthalmol"},{"key":"861_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ejca.2016.06.018","volume":"65","author":"U Urner-Bloch","year":"2016","unstructured":"Urner-Bloch U, Urner M, Jaberg-Bentele N, Frauchiger AL, Dummer R, Goldinger SM. MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: long-term ophthalmic effects. Eur J Cancer. 2016 Sep;65:130\u20138.","journal-title":"Eur J Cancer"},{"key":"861_CR15","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3892\/ijmm_00000191","volume":"23","author":"Q Jiang","year":"2009","unstructured":"Jiang Q, Cao C, Lu S, et al. MEK\/ERK pathway mediates UVB-induced AQP1 downregulation and water permeability impairment in human retinal pigment epithelial cells. Int J Mol Med. 2009;23:771\u20137.","journal-title":"Int J Mol Med"},{"key":"861_CR16","doi-asserted-by":"publisher","first-page":"801787","DOI":"10.1155\/2014\/801787","volume":"2014","author":"AV Kuznetsova","year":"2014","unstructured":"Kuznetsova AV, Kurinov AM, Aleksandrova MA. Cell models to study regulation of cell transformation in pathologies of retinal pigment epithelium. J Ophthalmol. 2014;2014:801787.","journal-title":"J Ophthalmol"},{"key":"861_CR17","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1089\/jop.2009.0060","volume":"25","author":"W Huang","year":"2009","unstructured":"Huang W, Yang AH, Matsumoto D, et al. PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion. J Ocul Pharmacol Ther. 2009;25:519\u201330.","journal-title":"J Ocul Pharmacol Ther"},{"key":"861_CR18","unstructured":"National_Cancer_Institute. Common Terminology Criteria for Adverse Events v4.0. NCI, NIH, DHHS. NIH publication # 09\u20137473, 29 May 2009."}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-018-0861-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12886-018-0861-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-018-0861-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T23:07:15Z","timestamp":1568416035000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-018-0861-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":18,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["861"],"URL":"https:\/\/doi.org\/10.1186\/s12886-018-0861-8","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"14 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent obtained from person reported in case presentation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"221"}}